Skip to content
biosimilar development

Biosimilars, Biologics, FDA Policy and Approvals, Clinical Trials, and Specialty Pharmacy

  • Home
    • Home
  • About BR&R
  • Biosimilar Approval Status
  • BR&R Product Profiles
    • Abrilada
    • Amjevita
    • Avasola
    • Cyltezo
    • Erelzi
    • Eticovo
    • Fulphila
    • Hadlima
    • Herzuma
    • Hyrimoz
    • Inflectra
    • Kanjinti
    • Mvasi
    • Nivestym
    • Ogivri
    • Ontruzant
    • Renflexis
    • Retacrit
    • Ruxience
    • Trazimera
    • Truxima
    • Udenyca
    • Zarxio
    • Ziextenzo
    • Zirabev
  • Contact Us
  • The Biosimilars Market Report Is Available Now!
  • $0.00 0 items

Cart

Your cart is currently empty.

Return to shop

Recent Posts

  • Samsung Bioepis Announces Interim Phase 3 Study Results for Ranibizumab Biosimilar May 19, 2020
  • Biosimilar Switching: The Evidence on Its Utility and Safety Keeps Rolling in May 11, 2020
  • Updates on Some Lesser-Known Manufacturers’ Plans for Biosimilars in the US May 4, 2020
  • Prescription Abandonment and the Economic Effects of COVID-19 April 27, 2020
  • An Interesting Comparison: The Latest Data on US and EU Biosimilar Uptake April 23, 2020
  • Partners Merck and Samsung Bioepis Launch Fifth Trastuzumab Biosimilar April 15, 2020
  • Patient Cost-Sharing “Advantage” Can Only Exist in a Biosimilar World Without Rebates April 3, 2020
  • One Academic Medical Center’s Clinical Experience and Savings With Biosimilar Infliximab April 1, 2020
  • Transition Day for Insulins, Other Products March 24, 2020
  • A Conversation With Christine M. Simmon, Executive Director, Biosimilars Council and Senior VP, Policy and Strategic Alliances, Association for Accessible Medicines March 24, 2020

Recent Comments

Prof. Dr. Arnold G.… on Biosimilar Switching: The Evid…
STEVEN J. MILLER on Prescription Abandonment and t…
Nesta on Bevacizumab ASP Pricing now Dr…
Steve Miller on Partners Teva and Celltrion An…
FiercePharmaPolitics… on How Did Kaiser Permanente Reac…

Archives

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Top Posts & Pages

  • Biosimilar Approval Status
  • How Did Kaiser Permanente Reach 95%+ Utilization of Biosimilar Herceptin and Avastin so Quickly?
  • Ruxience
  • Who Are the Key Lucentis Biosimilar Players to Watch?
  • Bevacizumab ASP Pricing now Dropping With Biosimilar Entries
  • The Evolution of the Biosimilars Market
  • An Interesting Comparison: The Latest Data on US and EU Biosimilar Uptake
  • Partners Merck and Samsung Bioepis Launch Fifth Trastuzumab Biosimilar
  • Truxima
  • Cart
Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookie Policy

Follow Us

  • Twitter
  • LinkedIn
  • Home
  • About BR&R
  • Biosimilar Approval Status
  • Contact Us
  • Terms and Conditions

Copyright

Copyright 2015-2020 by SM Health Communications. All Rights Reserved

Powered by WordPress.com.